EPAS1 and nonpapillary renal cell carcinoma: Sunitinib, the first‐line treatment of ccRCC, targets vascular endothelial growth factor receptor (VEGFR) and platelet‐derived growth factor receptor (PDGFR), which are both downstream genes of HIF2α.86, 87